Oncogene-Directed Alterations in Cancer Cell Metabolism

Trends in Cancer - Tập 2 Số 7 - Trang 365-377 - 2016
Arvindhan Nagarajan1, Parmanand Malvi1, Narendra Wajapeyee1,2
1Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
2Yale Cancer Center, Yale University School of Medicine, New Haven, CT 06510, USA

Tóm tắt

Từ khóa


Tài liệu tham khảo

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9

Dang, 2012, MYC on the path to cancer, Cell, 149, 22, 10.1016/j.cell.2012.03.003

Brodeur, 1984, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, Science, 224, 1121, 10.1126/science.6719137

Kohl, 1984, Activated expression of the N-myc gene in human neuroblastomas and related tumors, Science, 226, 1335, 10.1126/science.6505694

Park, 2004, Determination of binding constant of transcription factor myc-max/max-max and E-box DNA: the effect of inhibitors on the binding, Biochim. Biophys. Acta, 1670, 217, 10.1016/j.bbagen.2003.12.007

Nakagawara, 1987, N-myc oncogene amplification and catecholamine metabolism in children with neuroblastoma, Lancet, 1, 559, 10.1016/S0140-6736(87)90195-4

Nakagawara, 1990, Inverse correlation between N-myc amplification and catecholamine metabolism in children with advanced neuroblastoma, Surgery, 107, 43

Tonini, 1987, N-myc oncogene amplification and catecholamine metabolism in patients with neuroblastoma, Lancet, 2, 795, 10.1016/S0140-6736(87)92521-9

Pusch, 1997, Cellular targets for activation by c-Myc include the DNA metabolism enzyme thymidine kinase, DNA Cell Biol., 16, 737, 10.1089/dna.1997.16.737

Shim, 1997, c-Myc transactivation of LDH-A: implications for tumor metabolism and growth, Proc. Natl. Acad. Sci. U.S.A., 94, 6658, 10.1073/pnas.94.13.6658

Maya-Mendoza, 2015, Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress, Mol. Oncol., 9, 601, 10.1016/j.molonc.2014.11.001

Edmunds, 2014, c-Myc programs fatty acid metabolism and dictates acetyl-CoA abundance and fate, J. Biol. Chem., 289, 25382, 10.1074/jbc.M114.580662

de la Cova, 2014, Supercompetitor status of Drosophila Myc cells requires p53 as a fitness sensor to reprogram metabolism and promote viability, Cell Metab., 19, 470, 10.1016/j.cmet.2014.01.012

Liu, 2012, Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC, Proc. Natl. Acad. Sci. U.S.A., 109, 8983, 10.1073/pnas.1203244109

Gao, 2009, c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism, Nature, 458, 762, 10.1038/nature07823

Mannava, 2008, Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells, Cell Cycle, 7, 2392, 10.4161/cc.6390

Shroff, 2015, MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism, Proc. Natl. Acad. Sci. U.S.A., 112, 6539, 10.1073/pnas.1507228112

Curtin, 2005, Distinct sets of genetic alterations in melanoma, N. Engl. J. Med., 353, 2135, 10.1056/NEJMoa050092

Neri, 1988, Analysis of RAS oncogene mutations in human lymphoid malignancies, Proc. Natl. Acad. Sci. U.S.A., 85, 9268, 10.1073/pnas.85.23.9268

Bacher, 2006, Implications of NRAS mutations in AML: a study of 2502 patients, Blood, 107, 3847, 10.1182/blood-2005-08-3522

Guo, 2013, Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation, Nat. Genet., 45, 1459, 10.1038/ng.2798

Agrawal, 2011, Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1, Science, 333, 1154, 10.1126/science.1206923

Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766

Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969

Pakala, 1988, Polyamine metabolism and interconversion in NIH 3T3 and ras-transfected NIH 3T3 cells, Cancer Res., 48, 3336

Chiarugi, 1989, Signal transduction in EJ-H-ras-transformed cells: de novo synthesis of diacylglycerol and subversion of agonist-stimulated inositol lipid metabolism, FEBS Lett., 252, 129, 10.1016/0014-5793(89)80904-4

Huang, 1988, Enhancement of inositol phospholipid metabolism and activation of protein kinase C in ras-transformed rat fibroblasts, J. Biol. Chem., 263, 17975, 10.1016/S0021-9258(19)81311-X

Milligan, 1989, Identification of the pertussis and cholera toxin substrates in normal and N-ras transformed NIH3T3 fibroblasts and an assessment of their involvement in bombesin-stimulation of inositol phospholipid metabolism, Oncogene, 4, 659

Chiaradonna, 2006, Ras-dependent carbon metabolism and transformation in mouse fibroblasts, Oncogene, 25, 5391, 10.1038/sj.onc.1209528

Ying, 2012, Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism, Cell, 149, 656, 10.1016/j.cell.2012.01.058

Son, 2013, Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway, Nature, 496, 101, 10.1038/nature12040

Commisso, 2013, Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells, Nature, 497, 633, 10.1038/nature12138

Lim, 2011, Macropinocytosis: an endocytic pathway for internalising large gulps, Immunol. Cell. Biol., 89, 836, 10.1038/icb.2011.20

Haq, 2013, Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF, Cancer Cell, 23, 302, 10.1016/j.ccr.2013.02.003

Scott, 2011, Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect, J. Biol. Chem., 286, 42626, 10.1074/jbc.M111.282046

Trousil, 2015, Addicted to AA (Acetoacetate): A Point of Convergence between Metabolism and BRAF Signaling, Mol. Cell, 59, 333, 10.1016/j.molcel.2015.07.024

Kang, 2015, Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling, Mol. Cell, 59, 345, 10.1016/j.molcel.2015.05.037

Kaplon, 2013, A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence, Nature, 498, 109, 10.1038/nature12154

Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382

Mardis, 2009, Recurring mutations found by sequencing an acute myeloid leukemia genome, N. Engl. J. Med., 361, 1058, 10.1056/NEJMoa0903840

Yan, 2009, IDH1 and IDH2 mutations in gliomas, N. Engl. J. Med., 360, 765, 10.1056/NEJMoa0808710

Locasale, 2011, Metabolic flux and the regulation of mammalian cell growth, Cell Metab., 14, 443, 10.1016/j.cmet.2011.07.014

Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309

Hsu, 2008, Cancer cell metabolism: Warburg and beyond, Cell, 134, 703, 10.1016/j.cell.2008.08.021

Kennedy, 2010, Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation, Future Oncol., 6, 127, 10.2217/fon.09.145

van Horssen, 2013, Cancer cell metabolism regulates extracellular matrix degradation by invadopodia, Eur. J. Cell Biol., 92, 113, 10.1016/j.ejcb.2012.11.003

Cardone, 2005, The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis, Nat. Rev. Cancer, 5, 786, 10.1038/nrc1713

Lu, 2002, Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis, J. Biol. Chem., 277, 23111, 10.1074/jbc.M202487200

Colegio, 2014, Functional polarization of tumour-associated macrophages by tumour-derived lactic acid, Nature, 513, 559, 10.1038/nature13490

Vega-Naredo, 2014, Mitochondrial metabolism directs stemness and differentiation in P19 embryonal carcinoma stem cells, Cell Death Differ., 21, 1560, 10.1038/cdd.2014.66

Hamanaka, 2012, Targeting glucose metabolism for cancer therapy, J. Exp. Med., 209, 211, 10.1084/jem.20120162

Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. U.S.A., 92, 5510, 10.1073/pnas.92.12.5510

Kaelin, 2008, Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway, Mol. Cell, 30, 393, 10.1016/j.molcel.2008.04.009

Su, 1990, Elevation of facilitated glucose-transporter messenger RNA in human hepatocellular carcinoma, Hepatology, 11, 118, 10.1002/hep.1840110120

Yamamoto, 1990, Over-expression of facilitative glucose transporter genes in human cancer, Biochem. Biophys. Res. Commun., 170, 223, 10.1016/0006-291X(90)91263-R

Nishioka, 1992, Distribution of the glucose transporters in human brain tumors, Cancer Res., 52, 3972

Xu, 2011, Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases, Cancer Cell, 19, 17, 10.1016/j.ccr.2010.12.014

Cardaci, 2012, TCA Cycle Defects and Cancer: When Metabolism Tunes Redox State, Int. J. Cell Biol., 2012, 161837, 10.1155/2012/161837

Duvel, 2010, Activation of a metabolic gene regulatory network downstream of mTOR complex 1, Mol. Cell, 39, 171, 10.1016/j.molcel.2010.06.022

Stanton, 1991, Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity, J. Biol. Chem., 266, 12442, 10.1016/S0021-9258(18)98918-0

Lin, 2015, 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling, Nat. Cell Biol., 17, 1484, 10.1038/ncb3255

Horton, 2003, Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes, Proc. Natl. Acad. Sci. U.S.A., 100, 12027, 10.1073/pnas.1534923100

Hatzivassiliou, 2005, ATP citrate lyase inhibition can suppress tumor cell growth, Cancer Cell, 8, 311, 10.1016/j.ccr.2005.09.008

Chajes, 2006, Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival, Cancer Res., 66, 5287, 10.1158/0008-5472.CAN-05-1489

Vander Haar, 2007, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40, Nat. Cell Biol., 9, 316, 10.1038/ncb1547

Shaw, 2004, The LKB1 tumor suppressor negatively regulates mTOR signaling, Cancer Cell, 6, 91, 10.1016/j.ccr.2004.06.007

Wullschleger, 2006, TOR signaling in growth and metabolism, Cell, 124, 471, 10.1016/j.cell.2006.01.016

Bar-Peled, 2014, Regulation of mTORC1 by amino acids, Trends Cell Biol., 24, 400, 10.1016/j.tcb.2014.03.003

Amelio, 2014, Serine and glycine metabolism in cancer, Trends Biochem. Sci., 39, 191, 10.1016/j.tibs.2014.02.004

Uyttenhove, 2003, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nat. Med., 9, 1269, 10.1038/nm934

Dillon, 2004, Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation, Cancer, 100, 826, 10.1002/cncr.20057

Komada, 1997, Apoptotic cell death of human T lymphoblastoid cells induced by arginine deiminase, Int. J. Hematol., 65, 129, 10.1016/S0925-5710(96)00538-5

Zhang, 2013, Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma, Br. J. Cancer, 109, 14, 10.1038/bjc.2013.293

Knelson, 2014, Heparan sulfate signaling in cancer, Trends Biochem. Sci., 39, 277, 10.1016/j.tibs.2014.03.001

Haimovitz-Friedman, 1997, Ceramide signaling in apoptosis, Br. Med. Bull., 53, 539, 10.1093/oxfordjournals.bmb.a011629

Ponzoni, 1995, Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation, Cancer Res., 55, 853

Dhillon, 2007, MAP kinase signalling pathways in cancer, Oncogene, 26, 3279, 10.1038/sj.onc.1210421

Li, 2015, Targeting AMPK for cancer prevention and treatment, Oncotarget, 6, 7365, 10.18632/oncotarget.3629

Chiacchiera, 2010, The AMPK-FoxO3A axis as a target for cancer treatment, Cell Cycle, 9, 1091, 10.4161/cc.9.6.11035

Morales, 2015, Metformin in cancer treatment and prevention, Annu. Rev. Med., 66, 17, 10.1146/annurev-med-062613-093128

Zhang, 2012, Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis, J. Clin. Endocrinol. Metab., 97, 2347, 10.1210/jc.2012-1267

Yang, 2011, Metformin for cancer prevention, Front Med., 5, 115, 10.1007/s11684-011-0112-3

Faller, 2015, mTORC1-mediated translational elongation limits intestinal tumour initiation and growth, Nature, 517, 497, 10.1038/nature13896

Cloughesy, 2008, Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma, PLoS Med., 5, e8, 10.1371/journal.pmed.0050008

Wick, 1957, Localization of the primary metabolic block produced by 2-deoxyglucose, J. Biol. Chem., 224, 963, 10.1016/S0021-9258(18)64988-9

Pelicano, 2006, Glycolysis inhibition for anticancer treatment, Oncogene, 25, 4633, 10.1038/sj.onc.1209597

Vlodavsky, 1994, Inhibition of tumor metastasis by heparanase inhibiting species of heparin, Invasion Metastasis, 14, 290

Ott, 2013, Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma, Invest. New Drugs, 31, 425, 10.1007/s10637-012-9862-2

Yau, 2013, A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma, Invest. New Drugs, 31, 99, 10.1007/s10637-012-9807-9

Agrawal, 2003, A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma, Cancer, 98, 94, 10.1002/cncr.11480